title: Neutralization of prostaglandin E1 intravenous solution reduces infusion phlebitis.
abstract: Previous studies have shown moderate or severe phlebitis at the site of venipuncture in some patients who receiving prostaglandin E1 (PGE1) infusion therapy. Such phlebitis is sometimes severe enough to necessitate the cessation of PGE1 therapy. This study investigated how to continue PGE1 infusion therapy for 3 weeks with tolerable phlebitis. Although a 60 microg dose of PGE1 is usually dissolved in 500 mL of fluid to avoid phlebitis, we used 200 mL to prevent volume overload. This PGE1 solution was neutralized to pH 7.4 with 4 mL of 7% sodium bicarbonate. We examined the frequency and severity of phlebitis among patients who received a 2-h PGE1 infusion twice daily. Eighteen patients who were hospitalized for peripheral vascular disease between June 1998 and May 1999 were studied. All of them were men and their mean age was 63.3 +/- 8.9 years (range: 47-78 years). Fourteen patients had arteriosclerosis obliterans and four had Buerger's disease. When the severity of phlebitis was determined according to Dinley's criteria, two patients (11%) had grade 0, four patients (22%) had grade 1, eleven patients (61%) had grade 2, and one patient (6%) had grade 3 phlebitis. Usually, PGE1 infusion therapy is stopped when phlebitis reaches grade 4 or more, but there were no such cases in this study. We also found that aging was significantly correlated with a decrease in the severity of phlebitis (Spearman's rank correlation test: r = -0.545, p = 0.0193).
authors.affiliation: Department of Surgery II, National Defense Medical College, Tokorozawa, Saitama, Japan. BXB01424@nifty.ne.jp
authors.forename: M
authors.initials: M
authors.lastname: Fujita
authors.forename: N
authors.initials: N
authors.lastname: Hatori
authors.forename: M
authors.initials: M
authors.lastname: Shimizu
authors.forename: H
authors.initials: H
authors.lastname: Yoshizu
authors.forename: D
authors.initials: D
authors.lastname: Segawa
authors.forename: T
authors.initials: T
authors.lastname: Kimura
authors.forename: Y
authors.initials: Y
authors.lastname: Iizuka
authors.forename: S
authors.initials: S
authors.lastname: Tanaka
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000527:Alprostadil / Q000008:administration & dosage / Q000009:adverse effects*; D001157:Arterial Occlusive Diseases / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007262:Infusions, Intravenous; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D014677:Pharmaceutical Vehicles; D010689:Phlebitis / Q000139:chemically induced* / Q000517:prevention & control; D018962:Phlebotomy; D012307:Risk Factors; D017693:Sodium Bicarbonate / Q000008:administration & dosage*; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D014677:Pharmaceutical Vehicles; D014665:Vasodilator Agents; D017693:Sodium Bicarbonate; D000527:Alprostadil